Jasper Therapeutics Inc
NASDAQ:JSPR
Jasper Therapeutics Inc
NASDAQ:JSPR
Price:
1.05
USD
12.61%
Market Cap:
$29.4m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Jasper Therapeutics Inc
NASDAQ:JSPR
|
US |
|
Challenger Energy Group PLC
LSE:CEG
|
IM |
|
Intrum AB
OTC:INJJF
|
SE |
|
Pharmacielo Ltd
XTSX:PCLO
|
CA |
|
Eguana Technologies Inc
XTSX:EGT
|
CA |
Cash Flow Statement
Cash Flow Statement
Jasper Therapeutics Inc
Jasper Therapeutics Inc
Currency: USD
| Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | |||||||||||||||||||||
| Net Income |
(41)
|
(39)
|
(32)
|
(31)
|
(23)
|
(25)
|
(34)
|
(38)
|
(50)
|
(55)
|
(61)
|
(64)
|
(64)
|
(62)
|
(64)
|
(71)
|
(79)
|
(91)
|
(91)
|
(76)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Stock-Based Compensation |
2
|
2
|
2
|
1
|
2
|
2
|
3
|
4
|
5
|
5
|
6
|
5
|
5
|
5
|
6
|
7
|
7
|
8
|
7
|
7
|
|
| Other Non-Cash Items |
16
|
14
|
2
|
(5)
|
(19)
|
(19)
|
(13)
|
(8)
|
4
|
5
|
6
|
6
|
5
|
5
|
6
|
7
|
8
|
8
|
8
|
3
|
|
| Change in Working Capital |
1
|
(0)
|
5
|
2
|
(0)
|
(1)
|
(2)
|
(1)
|
3
|
3
|
5
|
5
|
1
|
0
|
(2)
|
0
|
(0)
|
8
|
6
|
(5)
|
|
| Cash from Operating Activities |
(24)
N/A
|
(25)
-3%
|
(24)
+3%
|
(34)
-38%
|
(42)
-24%
|
(45)
-9%
|
(48)
-6%
|
(46)
+4%
|
(42)
+8%
|
(46)
-9%
|
(48)
-5%
|
(52)
-8%
|
(57)
-10%
|
(56)
+3%
|
(58)
-4%
|
(63)
-8%
|
(70)
-11%
|
(73)
-5%
|
(76)
-4%
|
(77)
-1%
|
|
| Investing Cash Flow | |||||||||||||||||||||
| Capital Expenditures |
(1)
|
(1)
|
(2)
|
(2)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
0
|
(0)
|
(0)
|
(0)
|
|
| Other Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash from Investing Activities |
(1)
N/A
|
(1)
-30%
|
(2)
-38%
|
(2)
-41%
|
(1)
+38%
|
(1)
+3%
|
(1)
+17%
|
(1)
+52%
|
(1)
+1%
|
(0)
+40%
|
(0)
+65%
|
(0)
-124%
|
(0)
+0%
|
(0)
-55%
|
(1)
-67%
|
(1)
+22%
|
(1)
+5%
|
(0)
+31%
|
(0)
+79%
|
0
N/A
|
|
| Financing Cash Flow | |||||||||||||||||||||
| Net Issuance of Common Stock |
22
|
22
|
22
|
11
|
0
|
0
|
0
|
0
|
102
|
102
|
102
|
102
|
48
|
48
|
48
|
48
|
1
|
7
|
35
|
34
|
|
| Other |
0
|
(1)
|
91
|
90
|
0
|
91
|
(1)
|
0
|
0
|
(1)
|
(1)
|
(1)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash from Financing Activities |
22
N/A
|
21
-5%
|
113
+438%
|
101
-10%
|
90
-11%
|
91
+1%
|
(1)
N/A
|
0
N/A
|
102
+184 542%
|
101
0%
|
101
+0%
|
101
0%
|
47
-54%
|
47
+1%
|
47
0%
|
48
+1%
|
1
-99%
|
7
+1 118%
|
35
+435%
|
34
-2%
|
|
| Change in Cash | |||||||||||||||||||||
| Net Change in Cash |
(3)
N/A
|
(6)
-65%
|
86
N/A
|
65
-25%
|
47
-27%
|
44
-6%
|
(50)
N/A
|
(46)
+7%
|
59
N/A
|
55
-7%
|
53
-4%
|
49
-8%
|
(11)
N/A
|
(9)
+18%
|
(11)
-26%
|
(15)
-34%
|
(70)
-357%
|
(67)
+3%
|
(42)
+38%
|
(43)
-3%
|
|
| Free Cash Flow | |||||||||||||||||||||
| Free Cash Flow |
(25)
N/A
|
(27)
-4%
|
(26)
+1%
|
(36)
-38%
|
(43)
-20%
|
(47)
-8%
|
(49)
-5%
|
(46)
+5%
|
(43)
+8%
|
(46)
-9%
|
(48)
-5%
|
(52)
-8%
|
(58)
-10%
|
(56)
+3%
|
(59)
-4%
|
(63)
-8%
|
(70)
-10%
|
(74)
-6%
|
(77)
-4%
|
(77)
-1%
|
|
Switch to:
Switch to:
See Also
Discover More
